Renal Cell Carcinoma - Medicare Access (Medicare patients only)

Treatments Covered

  • Afinitor
  • Avastin
  • Axitinib
  • Bavencio
  • Bevacizumab
  • Bevacizumab-awwb
  • Cabometyx
  • Carboplatin
  • Cometriq
  • Depo-provera
  • Doxil
  • Everolimus
  • Fotivda
  • Gemzar
  • Inlyta
  • Intron-a
  • Keytruda
  • Lenvatinib
  • Lenvima
  • Medroxyprogesterone
  • Mvasi
  • Nexavar
  • Nivolumab
  • Opdivo
  • Opdivo/yervoy
  • Paclitaxel
  • Platinol
  • Proleukin
  • Roferon-a
  • Sutent
  • Tarceva
  • Torisel
  • Votrient
  • Welireg
  • Xgeva
  • Zirabev

Fund Definition

Assistance with the prescription drugs and biologics used in the treatment of renal cell carcinoma.

Grant Utilization

HealthWell estimates that patients use an average of $7,020 during their 12-month grant period for this disease area.

Consider Premium Assistance

Under this fund, HealthWell can assist with premium costs. Medicare supplemental policies can help with cost shares related to many aspects of your health care. Using a HealthWell grant to cover premiums may be a better option than treatment-specific cost shares.

Do I Qualify?

HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:

  • Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Disease Funds listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.

  • This is a Medicare Access Fund. In order to qualify for assistance through this fund, you must have Medicare. The Foundation will refer patients without Medicare to other programs, such as manufacturer patient assistance programs.

  • HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, please call (800) 675-8416 to speak with a HealthWell representative.
  • If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.

About Renal Cell Carcinoma

According to the National Kidney Foundation, RCC is the most common type of kidney cancer in adults. About 30 percent of people who are diagnosed with RCC develop advanced (metastatic) disease, in which the cancer spreads to other parts of the body— most often the bones or lungs. Kidney cancer is usually treated with a combination of nephrectomy (surgical removal of all or part of the kidney), radiation therapy, immunotherapy, chemotherapy and hormone therapy. Kidney cancer can often be cured if found and treated before it has spread. Source: National Kidney Foundation

Additional Resources

You may also visit our Resource List to view other copayment organizations that may provide assistance.

Close menu